It’s time to invest in cessation: the global investment case for tobacco cessation. by unknown
1







It’s time to invest in cessation: the global investment case for tobacco cessation
ISBN 978-92-4-003928-5 (electronic version)
ISBN 978-92-4-003929-2 (print version)
© World Health Organization 2021
Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC 
BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). 
Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work 
is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific 
organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work 
under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer 
along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for 
the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. 
Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World 
Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).
Suggested citation. It’s time to invest in cessation: the global investment case for tobacco cessation. Geneva: World Health 
Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use 
and queries on rights and licensing, see https://www.who.int/copyright. 
Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it 
is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The 
risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.
General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression 
of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or 
concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for 
which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended 
by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary 
products are distinguished by initial capital letters.
All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published 
material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of 
the material lies with the reader. In no event shall WHO be liable for damages arising from its use. 
Acknowledgements
The World Health Organization (WHO) acknowledges with thanks all those who contributed to the preparation of this document. 
Particular thanks are due to the following people, who helped to bring the document to fruition.
Ruediger Krech, Director of the Health Promotion Department, and Etienne Krug, Director of the Social Determinants of Health 
Department, who oversaw the creation of the document.
Data analysis: Guillermo Sandoval, Robert Totanes, and Dongbo Fu
Writer: Annette David
WHO reviewers: Vinayak Prasad, Virginia Arnold, Douglas Bettcher, Susannah Robinson, Jeremias Paul, and Tessa Edejer 
This document has been made possible through funding provided by Bloomberg Philanthropies.
3
THE GLOBAL INVESTMENT CASE  
FOR TOBACCO CESSATION
Helping people to quit tobacco use is vital to ending the 
tobacco epidemic. Tobacco cessation is a critical public health 
investment. It saves lives, protects health and ultimately, saves 
governments money. 
The entry into force in 2005 of the WHO Framework Convention on Tobacco Control 
(FCTC) – WHO’s first global health treaty – has accelerated global progress in 
reducing tobacco use.1 Largely, these gains have come through the adoption of key 
demand reduction strategies highlighted in the MPOWER package. 
Despite significant progress in the last 15 years, there are still 1.3 billion tobacco users 
today, trapped by nicotine’s addictiveness and the manipulative influence of the tobacco 
industry. Helping them quit tobacco use is the key to breaking this cycle of dependence.
Investing in six key tobacco cessation interventions could help millions of tobacco users 
quit successfully, save millions of lives, and offer a significant return on investment 
for governments. These include three population-level approaches (i.e. brief advice 
in primary care, national toll-free quit lines and mCessation) and 3 pharmacologic 
interventions (i.e. nicotine replacement therapy (NRT), Bupropion, and Varenicline).
This document presents the case for why countries should invest in tobacco cessation 
from health and economic perspectives. It presents data from a return-on-investment 
(ROI) analysis of 124 low- and middle-income countries. The approach builds on 
previous methodologies and tools developed over the past two decades to support the 
implementation of the WHO ‘best buy’ interventions for noncommunicable diseases 
(NCDs), for which tobacco use is a major risk factor.2
MPOWER
MPOWER is an acronym 
that represents key 
policy strategies proven 
to effectively reduce the 
demand for tobacco, based 
on provisions from the WHO 
Framework Convention on 
Tobacco Control.
The 6 MPOWER measures are:
Monitor tobacco use and prevention 
policies
Protect people from tobacco use
Offer help to quit tobacco use (Cessation)
Warn about the dangers of tobacco
Enforce bans on tobacco advertising, 
promotion and sponsorship
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WHY CESSATION  
MATTERS
THERE ARE STILL TOO MANY TOBACCO USERS.
Globally, the prevalence of tobacco use has decreased, with the fastest declines 
recorded in the years immediately following the entry into force of the WHO FCTC. 
However, these reductions in prevalence have been outpaced by population growth. 
This means that the number of smokers globally has increased from 0.99 billion in 1990 
to 1.14 billion in 2019.3 There are also approximately 302.5 million smokeless tobacco 
users worldwide.4
UNLESS CURRENT TOBACCO USERS QUIT,  
THE COSTS OF TOBACCO USE WILL CONTINUE TO RISE.
Tobacco users are at heightened risk for death, disability and chronic health issues 
due to NCDs such as ischaemic heart disease, chronic obstructive pulmonary disease, 
cancers and stroke, are the predominant causes of tobacco-attributable deaths. They 
are also the major contributors to tobacco-related health care costs. In 2019, tobacco 
caused nearly 8 million deaths and 200 million disability-adjusted life years (DALYs).4 
The total economic loss due to tobacco is estimated at US$ 1.4 trillion annually.5 
Without cessation, the health burden and costs of tobacco will continue to accrue.
CESSATION INTERVENTIONS ARE PROVEN TO WORK.
Nicotine addiction is powerful, but there are proven ways to help people break free 
from their tobacco dependence. Currently, accepted evidence-based cessation 
strategies include population-level interventions (brief advice, quit lines, mCessation), 
individual specialist approaches (intensive behavioral support, cessation clinics) and 
pharmacologic interventions (nicotine replacement therapies (NRTs) and non-nicotine 
pharmacotherapies). Implementing these measures has been shown to result in a 
2-15% increase in the proportion of tobacco users who quit tobacco use for 6 months or 
more, over no intervention.6 When applied universally over the global population of over 
a billion tobacco users, the absolute effect size would be considerable.
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TABLE 1  
INCLUDED CESSATION INTERVENTIONS WITH COVERAGE TARGETS AND EFFECT SIZES USED






























Brief advice Advice to stop using tobacco, usually taking 
only a few minutes, is given to all tobacco users 
during the course of a routine consultation and/or 
interaction with a physician or health care worker.





A national toll-free quit line is a telephone 
counselling service that can provide both 
proactive and reactive counselling.  
A reactive quit line provides an immediate 
response to a call initiated by the tobacco user, 
but only responds to incoming calls. A proactive 
quit line involves setting up a schedule of 
follow-up calls to tobacco users to provide 
ongoing support.
5% of all tobacco 
users aged 15+
5%
mCessation Tobacco cessation interventions are delivered 
via mobile phone text messaging. Mobile 
technologies provide the opportunity to expand 
access to a wider population, and text messaging 
can provide personalized tobacco cessation 
support in an efficient and cost-effective manner.




























NRTs are available in several forms including 
gum, lozenges, patches, inhalers and nasal 
spray. These cessation tools reduce craving 
and withdrawal symptoms by providing a low, 
controlled dose of nicotine without the toxins 
found in cigarettes. The doses of NRT are 
gradually reduced over time to help the tobacco 
user ween off of nicotine by getting used to less 
and less stimulation.
An additional 5% 
on top of estimated 
current NRT use 
among tobacco users 
aged 15+  
(varies per country)
6%
Bupropion Non-nicotine pharmacotherapy: These 
pharmacotherapies reduce cravings and 
withdrawal symptoms and decrease the 
pleasurable effects of cigarettes and other 
tobacco products.
An additional 1.5% 
on top of estimated 
current NRT use 
among tobacco users 
aged 15+  
(varies per country)
7%
Varenicline Non-nicotine pharmacotherapy: These 
pharmacotherapies reduce cravings and 
withdrawal symptoms and decrease the 
pleasurable effects of cigarettes and other 
tobacco products.
An additional 1.5% 
on top of estimated 
current NRT use 
among tobacco users 
aged 15+  
(varies per country)
15%
Adapted from the following source: WHO. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization; 2019. License: CC BY-NC-
SA 3.0 IGO.
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STRONGER TOBACCO CONTROL LAWS  
HAVE INCREASED PRESSURE ON TOBACCO USERS TO QUIT.
There are now 182 Parties to the WHO FCTC, covering 90% of the world’s population.7 
As these Parties increasingly enact and implement tobacco control policies, tobacco 
users’ intention to quit will continue to increase. Over 60% of smokers report that they 
want to quit, and over 40% have attempted to do so in the past year.8 However, many will 
fail without cessation assistance.
OFFERING CESSATION SUPPORT IS AN ETHICAL OBLIGATION.
Investing in proven cessation interventions now, to meet rising demand to quit tobacco 
use, is not just strategic. It is also an ethical obligation, providing those addicted to 
nicotine with the assistance and support that they need. The United Nations Member 
States pledged to ensure “no one will be left behind” and to “endeavour to reach the 
furthest behind first” when they adopted the 2030 Sustainable Development Goals.9 
Tobacco users are the ones who are being left behind in tobacco control. Without 
cessation support, they will continue to bear the brunt of tobacco’s harms.
NOT ENOUGH TOBACCO USERS HAVE ACCESS  
TO HIGH-QUALITY TOBACCO CESSATION SERVICES.
Ensuring tobacco cessation interventions reach the people who need them is a 
significant challenge. Currently, only about 30% of the world’s population has access to 
appropriate tobacco cessation services.10 Many countries still have no national tobacco 








THE NUMBERS  
SHOW
The models utilized in this study examined the impact of investing in three evidence-
based population-level tobacco cessation strategies and three pharmacologic 
interventions. The models looked at several parameters such as per capita costs, 
number of successful quitters, lives saved, and the economic benefits and returns 
on investment after a 10-year investment period (2021-2030) and until the cohort of 
quitters reaches the age of 65 years.11
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AN ADDITIONAL US$ 1.68 INVESTED IN ALL SIX CESSATION 
INTERVENTIONS (PER CAPITA PER YEAR FROM 2021 TO 2030)12 
WILL YIELD THE FOLLOWING:
BY 2030
152 MILLION
SMOKERS WILL HAVE BEEN 
HELPED TO QUIT TOBACCO USE
2.7 MILLION 
LIVES WILL  
HAVE BEEN SAVED
BENEFITS WILL ONTINUE TO ACCRUE INCREMENTALLY,  
BEYOND THE INVESTMENT PERIOD.  
BY THE TIME THE COHORT OF QUITTERS REACHES 65 YEARS OLD:
16 MILLION
LIVES WILL  
HAVE BEEN SAVED
EACH DOLLAR INVESTED  
WILL HAVE YIELDED
US$ 7.50 IN GAINS
THE THREE POPULATION-LEVEL CESSATION INTERVENTIONS COST LITTLE, 
THOUGH THEY DELIVER SIGNIFICANT RETURNS ON INVESTMENT WITHIN 10 YEARS, 
AND TREMENDOUS RETURNS BY THE TIME QUITTERS REACH 65 YEARS OF AGE.
On average, countries need  
to invest only 21 cents per  
capita annually on the three  
population-level interventions.
Each US$ 1  
investment yields  
US$ 3.58 in gains  
by 2030;
Each US$ 1 investment 
produces US$ 35.40 
in returns by the time 
quitters reach 65 years.
In total, population-level interventions can lead to 88 million successful quitters and  
1.4 million lives saved by 2030, and 9.3 million lives saved in total by the time quitters reach 65 years.  
Clearly, these three population-level interventions are highly cost-effective.
PHARMACOLOGIC CESSATION INTERVENTIONS  
(NRTS, BUPROPION AND VARENICLINE) COST MORE, BUT PRODUCE 
SUBSTANTIAL RETURNS DEMONSTRATED OVER THE LIFETIME OF QUITTERS:
The cost of investing  
in pharmacologic  
interventions is  
US $1.49 per capita annually.
The 10-year return on investment is 40 
cents for every dollar, but this increases 
to US$ 3.60 per dollar over the lifetime 
of the cohort of quitters; and
Pharmacologic interventions can produce up to 66 million more successful quitters and  
1.3 million lives saved by 2030, and 6.8 million lives saved when quitters reach 65 years of age.
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Lower-middle-income countries (LMICs) and low income countries (LICs) show positive 
but lower returns on investment than upper-middle-income countries (UMICs) for both 
population-level interventions and pharmacotherapies. However, the cost per capita is 
considerably less than for UMICs, and overall, more lives would be saved in LMICs/LICs.
INTERVENTIONS COST PER CAPITA 
(US$)
ROI AT AGE 65 
YEARS (US $)
LIVES SAVED 
UNTIL 65 YEARS 
(MILLIONS)
UMICs LMICs/LICs UMICs LMICs/LICs UMICs LMICs/LICs
All interventions 2.56 1.01 9.60 3.44 7.0 8.9
Population-level 
interventions 0.34 0.11 43.1 18.0 4.1 5.2
Pharmacologic 
interventions 2.25 0.92 4.60 1.66 3.0 3.8
If the cost of pharmacotherapies could be reduced, as has been achieved for medicines 







MEETING GLOBAL AND NATIONAL HEALTH GOALS  
HINGES ON INVESTING IN TOBACCO CESSATION TO INCREASE  
ITS AVAILABILITY TO ALL THE WORLD’S TOBACCO USERS.
WHO’s Member States endorsed the WHO Global Action Plan for the Prevention and 
Control of NCDs 2013–2020, extended recently by the World Health Assembly to 2030, 
and the corresponding nine voluntary global targets to reduce NCD mortality. The 
agreed target for tobacco control is a 30% relative reduction in prevalence of current 
tobacco use in those aged 15 years and above between 2010 and 2025. The short time 
frame for attaining this target mandates aggressive promotion of cessation among 
current tobacco users to augment preventive strategies, which produce results long-
term. Countries also have set national targets for reducing tobacco use. Encouraging 
and supporting current tobacco users to quit is the means to reduce prevalence quickly, 
to meet the 2025 global goal and national health targets.
CESSATION IS NOT JUST ABOUT HEALTH;  
IT ALSO IMPACTS NATIONAL DEVELOPMENT.
The Sustainable Development Goals (SDGs) have already recognized tobacco’s pivotal 
role in hindering economic development. Tobacco use imposes high productivity costs 
on economies because tobacco-related illnesses diminish the workforce.  Over 80% 
of today’s tobacco users are in low and middle-income countries. When they die, the 
majority are in their most productive years (30-65 years). This implies that tobacco’s 
stranglehold on economic development is highest in developing countries.
Target 3.4 under SDG 3 (Good health and well-being) exhorts countries to reduce 
premature mortality from NCDs by one-third by 2030. Target 3A specifically 
highlights strengthening WHO FCTC implementation as a vital means to achieve 
this one-third reduction in NCD deaths. Cessation is fundamental to achieving these 
development targets.
TOBACCO CESSATION CAN SUPPORT EQUITY.
The tobacco epidemic is a marker of social inequity. Over 80% of tobacco users live in 
low- and middle-income countries, where cessation services are limited. The tobacco 
industry’s increasingly pervasive marketing and pricing strategies result in people from 
poorer households spending proportionately more on tobacco products. These same 
communities are also at far greater risk of experiencing health issues that require 
catastrophic spending in the future, and in these households the impact of lost earnings 
from poor health will be greater. Investing in cessation is a means to redress this 
inequity and its formidable adverse impact on health and development. 
12
BEHAVIOURAL COUNSELLING
One approach to help people who are trying to quit smoking is to offer them individual or 
group-based behavioural counselling and support using techniques which are supported 
by randomized control trials. Participants meet with a facilitator who is trained in smoking 
cessation counselling. Programme components are varied and can be offered one on 
one, through groups, online and face to face. There is good evidence through randomized 
control trials that  behavioural support interventions, across a range of intervention types 
and settings, delivered to an individual or to groups, are effective in helping people to stop 





DIGITAL CESSATION: A PROMISING APPROACH  
TO HELPING TOBACCO USERS QUIT TOBACCO USE
Digital tools for smoking cessation include text messaging, chat bots and apps. These 
can be accessed at any time, on technology platforms that smokers use already, and are 
easily scalable to populations. Most digital tools include information, behavior change 
techniques to distract users from cravings, motivation, rewards and support. There is good 
evidence that text messaging interventions for smoking cessation are effective [1]. These 
same techniques can also be incorporated into chatbots. WHO has developed a number 
of smoking cessation chatbots over the past year on common chatbot platforms including 
Viber, WhatsApp, Facebook messenger and free basics [2]. It has also developed it’s first 
digital health worker, Florence, who was designed to give additional information to smokers 
about quitting during COVID [3].There are over 500 apps for smoking cessation, and a 
number of them have good evidence for success based on randomized control trials and 
other criteria. Digital tools provide new opportunities to bring cessation into the hands of 
millions of smokers through their phones and other devices.
Source: [1] Whittaker R, McRobbie H, Bullen C, Rodgers A, Gu Y, Dobson R. Mobile phone text messaging and app‐based 




OTHER TOBACCO CESSATION INTERVENTIONS
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WHAT MEMBER STATES  
AND INVESTMENT PARTNERS  
CAN DO
Ending the tobacco epidemic requires investing in cessation. 
When employed in tandem with the other MPOWER measures, the O of MPOWER 
(cessation) assists tobacco users to quit successfully. It is an effective way to quickly 
reduce tobacco use prevalence, and to protect people from tobacco-related deaths, 
disability and chronic health problems.
Relatively small investments in tobacco cessation can yield large numbers of 
successful quitters, lives saved and significant returns on investment that continue to 
accrue – even after an initial 10-year investment period. Population-level interventions 
yield positive ROIs relatively quickly and need significantly lower per capita investments. 
Pharmacologic interventions cost more but result in considerable positive ROIs in the 
long-term. Thus, in resource-challenged settings, efforts should initially be directed 
towards the promotion of population-level cessation interventions. As resources 
and capacities grow, additional investments in pharmacologic interventions should be 
made since despite costing more, they can save additional lives and generate greater 






Cessation is often considered only possible in high-income countries. But these results 
show that it is the low and lower-middle-income countries that stand to gain 
the most in terms of lives saved. Governments and donors at all levels should see 
tobacco cessation as a key investment in public health and an opportunity to support 
these countries as a public health priority.
As countries around the world continue to strengthen tobacco control measures, the 
need for cessation services will only increase. Governments must help tobacco users 
secure access to tobacco cessation services that will potentially save their lives and 
livelihoods. Providing cessation support will also accelerate progress towards meeting 
global and national health and development targets, while helping to redress the social 
inequity wrought by tobacco use. 
We know the cost of inaction  
– millions of deaths every year.
We now know the cost of action  
– an additional US$ 1.68 per capita per year.
The case for investment in tobacco  
cessation has never been clearer. 
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